Literature DB >> 22823455

The burden and management of dyslipidemia: practical issues.

Alyssa B Schultz1, Chin-Yu Chen, Wayne N Burton, Dee W Edington.   

Abstract

The objective of this study is to describe briefly the burden of dyslipidemia, and to discuss and present strategies for health professionals to improve dyslipidemia management, based on a review of selected literature focusing on interventions for dyslipidemia treatment adherence. Despite the availability of effective lifestyle and pharmaceutical therapies for dyslipidemias, they continue to present a significant economic burden in the United States. Adherence to evidence-based guidelines for the treatment of dyslipidemias is unsatisfactory. The reasons for medication nonadherence are complex and specific to each patient. The lack of progress in achieving optimal lipid targets is caused by many factors: patient (medication adherence, cost of medication, literacy), medication (adverse effects, complexity of regimen), provider (lack of adherence to evidence-based practice guidelines, poor communication), and the US healthcare system (being focused on acute care rather than prevention, lack of continuity of care, general lack of use of an electronic health record). Combined interventions that target each part of the system have been effective in improving treatment adherence and achieving lipid goals. Patients, providers, pharmacists, and employers all play a role in management of dyslipidemia. No single approach will solve the complex issue of improving dyslipidemia management. The required lifestyle changes are known and effective medications are available. The challenge is for all interested parties-including nurses, nurse practitioners, doctors, pharmacists, other health care professionals, employers, and health plans-to help patients achieve behavioral changes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22823455     DOI: 10.1089/pop.2011.0081

Source DB:  PubMed          Journal:  Popul Health Manag        ISSN: 1942-7891            Impact factor:   2.459


  3 in total

1.  Dyslipidemia: blockbuster therapies are on the horizon.

Authors:  Rinki Patel; Kunj Gohil
Journal:  P T       Date:  2015-06

2.  Association between the MARS rs6782181 polymorphism and serum lipid levels.

Authors:  Jian Wu; Rui-Xing Yin; Tao Guo; Quan-Zhen Lin; Guang-Yuan Shi; Jia-Qi Sun; Shao-Wen Shen; Yi-Ming Wang; Hui Li; Jin-Zhen Wu
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

Review 3.  PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia.

Authors:  Matthew K Ito; Raul D Santos
Journal:  J Clin Pharmacol       Date:  2016-06-21       Impact factor: 3.126

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.